Review
Nutrition & Dietetics
Samia S. Messeha, Najla O. Zarmouh, Karam F. A. Soliman
Summary: Research on dietary polyphenolic compounds as antitumor agents is increasing due to the link between immunity and cancer. These compounds affect cancer progression and metastasis by inhibiting the EMT process, potentially reducing the risk of breast cancer.
Article
Dentistry, Oral Surgery & Medicine
So Mi Jeon, Je Sun Lim, Su Hwan Park, Hyung Joon Kim, Hyung-Ryong Kim, Jong-Ho Lee
Summary: PD-L1 and PD-1 signaling negatively regulate the osteo-/odontogenic differentiation of hDPSCs. Blocking PD-1 signaling enhances osteo-/odontogenic differentiation of hDPSCs, suggesting it as a potential therapeutic strategy.
INTERNATIONAL JOURNAL OF ORAL SCIENCE
(2022)
Article
Oncology
Ferdinand Blangero, Maud Robert, Thomas Andraud, Charles Dumontet, Hubert Vidal, Assia Eljaafari
Summary: Obesity increases the risk of cancer, including breast cancer. This study proposes a new mechanism in which mesenchymal stem cells from obese adipose tissue (ob-ASC) interact with immune cells, leading to inflammation and the activation of pathogenic cells double-secreting IL-17/IFN gamma. This interaction promotes breast cancer progression by enhancing cytokine secretion, angiogenic factor secretion, metalloproteinase expression, immune checkpoint overexpression, and cell migration in breast cancer cells.
Article
Medicine, General & Internal
Michal Adamczyk, Joanna Bartosinska, Dorota Raczkiewicz, Anna Michalak-Stoma, Dorota Krasowska
Summary: The PD-1 receptor and its ligands, PD-L1 and PD-L2, are involved in immune tolerance and prevention of immune-mediated diseases. This study found lower levels of PD-1 and PD-L1 expression in psoriatic patients compared to healthy individuals. Biologic therapy increased PD-L1 expression and decreased PD-1 expression. The disruption of the PD-1/PD-L1 pathway in psoriasis suggests its importance in disease development, and biologic drugs may reverse these abnormalities.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cell Biology
Meizhang Li, Rupal Soder, Sunil Abhyankar, Haitham Abdelhakim, Mitchell W. Braun, Camille V. Trinidad, Harsh B. Pathak, Ziyan Pessetto, Clayton Deighan, Siddhartha Ganguly, Buddhadeb Dawn, Joseph McGuirk, Neil Dunavin, Andrew K. Godwin
Summary: Research shows that MSCs derived from Wharton's Jelly secrete sEVs enriched in PD-L1, which play an immunomodulatory role by inhibiting T cell activation. Clinical data suggest that sEV-associated PD-L1 not only predicts outcomes from WJMSC therapy, but also has the potential for developing cell-independent therapies for aGvHD patients.
JOURNAL OF EXTRACELLULAR VESICLES
(2021)
Article
Oncology
Stephane Terry, Cecile Dalban, Nathalie Rioux-Leclercq, Julien Adam, Maxime Meylan, Stephanie Buart, Antoine Bougouin, Alexandra Lespagnol, Frederic Dugay, Irelka Colina Moreno, Guillaume Lacroix, James B. Lorens, Gro Gausdal, Wolf H. Fridman, Fathia Mami-Chouaib, Nathalie Chaput, Benoit Beuselinck, Sylvie Chabaud, Janice Barros-Monteiro, Yann Vano, Bernard Escudier, Catherine Sautes-Fridman, Laurence Albiges, Salem Chouaib
Summary: The study found that high AXL expression is associated with lower response rates and shorter progression-free survival following PD-1 blockade; AXL expression is strongly correlated with tumor PD-L1 expression, especially in tumors with VHL inactivation; Patients with tumors displaying both PD-L1 expression and high AXL expression had the worst overall survival.
CLINICAL CANCER RESEARCH
(2021)
Article
Multidisciplinary Sciences
Reza Mirzaei, Ashley Gordon, Franz J. Zemp, Mehul Kumar, Susobhan Sarkar, H. Artee Luchman, Anita C. Bellail, Chunhai Hao, Douglas J. Mahoney, Jeff F. Dunn, Pinaki Bose, V. Wee Yong
Summary: The study identified a population of cells coexpressing PD-1 and BTIC marker within the human glioblastoma microenvironment, with tumor-intrinsic PD-1 promoting proliferation and self-renewal of BTICs independently of PD-L1. Additionally, BTIC-intrinsic PD-1 accelerated intracranial tumor growth in mice lacking T and B cells, indicating a nonimmune resistance mechanism to PD-1 or PD-L1-blocking therapies in patients with glioblastoma.
Article
Medicine, Research & Experimental
Adam P. Curnock, Giovanna Bossi, Jyothi Kumaran, Lindsay J. Bawden, Rita Figueiredo, Rajeevkumar Tawar, Katherine Wiseman, Emma Henderson, Sec Julie Hoong, Veronica Gonzalez, Hemza Ghadbane, David Eo Knight, Ronan O'Dwyer, David X. Overton, Christina M. Lucato, Nicola Mg Smith, Carlos R. Reis, Keith Page, Lorraine M. Whaley, Michelle L. McCully, Stephen Hearty, Tara M. Mahon, Peter Weber
Summary: The study developed PD-1 agonist ImmTAAI molecules that can inhibit T cell function by mimicking the action of PD-L1. These molecules specifically bind to target cells and effectively activate the PD-1 receptor on interacting T cells, achieving immune suppression.
Article
Immunology
Z. Liu, F. Mi, M. Han, M. Tian, L. Deng, N. Meng, J. Luo, R. Fu
Summary: High expression of PD-L1 in BMSCs from patients with multiple myeloma may lead to apoptosis of CD8(+) T cells through the PD-1/PD-L1 axis, promoting immune escape in MM. The PD-L1 inhibitor can reverse BMSC-mediated suppression of CD8(+) T cells, enhancing their killing effect on MM cells.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Changsheng Huang, Shengxiang Ren, Yaqi Chen, Anyi Liu, Qi Wu, Tao Jiang, Panjing Lv, Da Song, Fuqing Hu, Jingqing Lan, Li Sun, Xue Zheng, Xuelai Luo, Qian Chu, Keyi Jia, Yan Li, Jun Wang, Caicun Zou, Junbo Hu, Guihua Wang
Summary: This research discovered that PD-L1 K162 was methylated by SETD7 and demethylated by LSD2. Additionally, PD-L1 K162 methylation controlled the PD1/PD-L1 interaction and significantly enhanced the suppression of T cell activity in controlling cancer immune surveillance. The study demonstrated that PD-L1 hypermethylation was the key mechanism for anti-PD-L1 therapy resistance, identified PD-L1 K162 methylation as a negative predictive marker for anti-PD-1 treatment in patients with non-small cell lung cancer, and showed that the PD-L1 K162 methylation:PD-L1 ratio was a more accurate biomarker for predicting anti-PD-(L)1 therapy sensitivity.
Editorial Material
Oncology
Junyun Lai, Paul A. Beavis, Jasmine Li, Phillip K. Darcy
Summary: Cancer immunotherapy has shown unprecedented clinical responses in patients with cancer, but some cancers remain refractory to these therapies. Combining adoptive T-cell therapy with checkpoint inhibition has become an innovative approach to overcome resistance in cancer treatment.
Article
Biochemistry & Molecular Biology
Bin Zhang, Ruenn Chai Lai, Wei Kian Sim, Andre Boon Hwa Choo, Ellen Birgit Lane, Sai Kiang Lim
Summary: The topical application of MSC exosomes significantly reduced levels of IL-17 and C5b-9 in a mouse model of psoriasis, potentially by inhibiting complement activation and the release of NETs from neutrophils in the stratum corneum.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Wei Xie, L. Jeffrey Medeiros, Shaoying Li, Guilin Tang, Guang Fan, Jie Xu
Summary: PD-1 ligands, including PD-L1 and PD-L2, are highly expressed in certain CD30+ large cell lymphomas, often due to genetic alterations in chromosome 9p24.1. The JAK/STAT pathway and mechanisms such as EBV infection and MAPK pathway activation also contribute to the overexpression of PD-L1 and PD-L2. Blockade of PD-1/PD-L1 has shown significant efficacy in treating relapsed/refractory lymphomas and may be a viable option for newly diagnosed patients.
Review
Immunology
Youliang Zhao, Yaqian Qu, Changfu Hao, Wu Yao
Summary: Fibrosis is a pathological process characterized by excessive accumulation of extracellular matrix, leading to permanent scarring and organ failure. The immune system, particularly the immune checkpoint molecule PD-1/PD-L1 axis, plays a crucial role in the initiation and progression of fibrosis. The therapeutic targeting of PD-1/PD-L1 axis for tumor immunotherapy has provided new insights for its potential use in fibrotic diseases. This review discusses the structure, function, and regulatory mechanism of PD-1 and PD-L1, and summarizes the research progress of PD-1/PD-L1 signaling in fibrotic diseases.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Endocrinology & Metabolism
Jun Fang, Lei Yu, Lan-Gen Zhuang, Xiao-Yan Pei, Qiong Wang, Guo-Xi Jin
Summary: This study analyzes the percentages of Th17 and Tregs, as well as the expression of PD-1/PD-L1, in HT patients. The results show an increase in Th17 percentage and a decrease in Tregs percentage in the HT group. Additionally, HT patients' Th17 express lower levels of PD-1, while their Tregs express higher levels of both PD-1 and PD-L1.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Multidisciplinary Sciences
Gyungah Kim, Yoon Shin Park, Yunki Lee, Yoon Mi Jin, Da Hyeon Choi, Kyung-Ha Ryu, Yoon Jeong Park, Ki Dong Park, Inho Jo
Article
Dermatology
Tae Young Han, June Hyunkyung Lee, Tai Kyung Noh, Min Wha Choi, Jae-Seung Yun, Kyung Ho Lee, Jung Min Bae
JOURNAL OF DERMATOLOGY
(2018)
Article
Multidisciplinary Sciences
Kyung-Ah Cho, Minhwa Park, Yu-Hee Kim, So-Youn Woo, Kyung-Ha Ryu
SCIENTIFIC REPORTS
(2017)
Article
Oncology
Kyung-Ah Cho, Yu-Hee Kim, Minhwa Park, Hye Ji Kim, So-Youn Woo, Joo-Won Park, Kyung-Ha Ryu
MOLECULAR MEDICINE REPORTS
(2019)
Article
Biochemistry & Molecular Biology
Minhwa Park, Kyung-Ah Cho, Yu-Hee Kim, Kyung Ho Lee, So-Youn Woo
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2020)
Article
Multidisciplinary Sciences
Minhwa Park, So-Youn Woo, Kyung-Ah Cho, Min-Sun Cho, Kyung Ho Lee
Article
Neurosciences
Kyung Ho Lee, Geun-Young Park, Won-Myong Bahk, Soo-Jung Lee, Chi-Un Pae
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE
(2020)
Article
Neurosciences
Kyung Ho Lee, Won-Myong Bahk, Soo-Jung Lee, Chi-Un Pae
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE
(2020)
Article
Neurosciences
Kyung Ho Lee, Won-Myong Bahk, Soo-Jung Lee, Alessandro Serretti, Chi-Un Pae
Summary: This study reports the results of pharmacogenomics-based antidepressant treatment in treatment-resistant major depressive disorder patients, demonstrating the clinical utility and benefit of PGXt in reducing depressive symptoms in some patients.
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE
(2021)
Letter
Dermatology
Hyo Jin Park, Kyung Ho Lee, Chul Jong Park
ANNALS OF DERMATOLOGY
(2022)
Article
Dermatology
Hyun Jeong Ju, Hyo Jin Park, In Hye Choi, Kyung Ho Lee, Mi Yeon Kwon, Chul Jong Park
Summary: This study found that the levels of Th1 and Th17 cytokines in tissues were increased in psoriasis patients compared to healthy controls. The increase in IFN-gamma mRNA levels in acute guttate psoriasis and the increase in IL-12 and IL-17A protein levels in chronic plaque psoriasis suggest that an imbalance between Th1 and Th17 cytokines may play a role in the phenotypic transition of psoriasis.
ANNALS OF DERMATOLOGY
(2022)
Article
Dermatology
Hyun Jin Kang, In Hye Choi, Chul Jong Park, Kyung Ho Lee
Summary: Acupuncture with gold threads for pain treatment is widely used in Asian countries, but the implanted threads can migrate and cause tissue damage. In a case study, it was found that gold threads injected on the back may have migrated to the leg through blood vessels, leading to edema. The condition improved gradually after treatment with steroids and antibiotics.
ANNALS OF DERMATOLOGY
(2021)
Proceedings Paper
Computer Science, Cybernetics
Jongin Lee, Daeki Cho, Junhong Kim, Eunji Im, JinYeong Bak, Kyung Ho Lee, Kwan Hong Lee, John Kim
PROCEEDINGS OF THE 2017 ACM SIGCHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS (CHI'17)
(2017)